The SHARE program will comprise two key elements:
- SHARE European Hypertension Survey, created by a European
steering committee of experts in the field of hypertension treatment,
to quantify and qualify the key challenges of getting hypertensive
patients to blood pressure goal, defining the real burden of
a) The survey consists of approximately 40 questions and will
take participants 10-15 minutes to complete (
b) The survey will be open to all European healthcare
professionals involved in the treatment of patients diagnosed with
essential hypertension (http://www.SHARE-hypertension.com).
- SHARE meeting series to debate the challenges of getting to blood
pressure goal and to postulate simple and effective solutions, which
will be communicated to the healthcare community, creating the right
combination for blood pressure control.
These two elements are interlinked to facilitate SHARE(ing) of best practice and simple, practical solutions. The outputs of the SHARE program are robust peer reviewed publications providing: (1) an overview of key European findings and solutions; (2) reviews of local variations and country best practices; and (3) a set of simple and effective recommendations for use by all European physicians so they can use the right combination to overcome the hurdles which have stopped their Challenging Patients getting to blood pressure goal.
To access the SHARE Survey, please visit: http://www.SHARE-hypertension.com
For more information on SHARE and The Challenging Patient, please visit:
1. WHO. The world health report 2002
2. Lawes CM, Vander Hoorn S, Rodgers A. Lancet 2008;371(9623):1513-8.
3. Allender et al. European Heart Network 2008
4. Redon etal. 2008 J Hypertens 26(12):S1-S14
5. ESH Scientific Newsletter 2007;8:No 3, http://www.eshonline.org/education/newsletter/2007_03.pdf
6. Neal et al Lancet 2000;356:1955-64, Prospective Studies Collaboration. Lancet 2002;360:1903-13
About DAIICHI SANKYO
DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of more than 5.9 billion EUR in fiscal year 2008, DAIICHI SANKYO is one of the world's 20 leading pharmaceutical companies. The company's world headquarters is in Tokyo, and its European base is located in Munich. DAIICHI SANKYO has affiliates in 12 European countries and has been one of the strongest Japanese pharmaceutical companies located in Europe since it set up European production facilities and marketing offices in 1990. The company's research activities focus on the areas of: cardiovascular diseases, hematology, diabetes, anti-infectives and cancer. Its aim is to develop medications that are "best" in their class or to create new classes of pharmaceutical drugs. For more information, please visit: http://www.daiichi-sankyo.eu